Fax: (713) 745-1163
Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy
Article first published online: 13 DEC 2005
Copyright © 2005 American Cancer Society
Volume 106, Issue 3, pages 552–558, 1 February 2006
How to Cite
Rohatgi, P. R., Swisher, S. G., Correa, A. M., Wu, T. T., Liao, Z., Komaki, R., Walsh, G. L., Vaporciyan, A. A., Rice, D. C., Bresalier, R. S., Roth, J. A. and Ajani, J. A. (2006), Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer, 106: 552–558. doi: 10.1002/cncr.21601
- Issue published online: 20 JAN 2006
- Article first published online: 13 DEC 2005
- Manuscript Accepted: 10 OCT 2005
- Manuscript Revised: 8 AUG 2005
- Manuscript Received: 11 JUL 2005
- Bristol-Myers Squibb Oncology
- Pfizer Oncology
- Rivercreek Foundation
- Smith, Park, Cantu, and Dallas Families
- esophageal carcinoma;
- preoperative chemoradiotherapy
The current study tested the hypothesis that the clinical outcome of patients with localized esophageal carcinoma after preoperative chemoradiotherapy (CTRT) depends on histology.
The authors stratified patients by adenocarcinoma (ACA) or squamous cell carcinoma (SCC) and compared the overall survival (OS) and patterns of failure among patients achieving pathologic complete response (pathCR) and < pathCR after preoperative CTRT. A correlation between baseline clinical stage and posttherapy pathologic response was made for ACA and SCC.
Of the 235 patients who underwent preoperative CTRT, 42 (18%) had SCC and 193 (82%) had ACA. In the ACA group, 56 patients (29%) achieved a pathCR and in the SCC group 13 patients (31%) achieved a pathCR. In the ACA group, a larger proportion of pathCR patients (n = 44; 79%) than < pathCR patients (n = 82; 60%) were alive at the time of last follow-up (P = 0.01) and pathCR patients had a longer OS than < pathCR patients (P = 0.0006). However, in the SCC group OS or proportion alive did not differ significantly between pathCR and < pathCR patients (P ≥ 0.05). In the ACA group, a greater portion of < pathCR patients (32%) than pathCR patients (16%) had distant metastases (P = 0.02) and the distant metastases-free survival of pathCR patients was longer than that of < pathCR patients (P = 0.0012). In the SCC group, the proportion or time to distant-metastases did not differ significantly. Pretreatment clinical stage did not correlate with pathologic response for either histology.
The results of the current study suggest that the clinical biology of SCC and ACA is different after CTRT. An investigation of molecular and patient genetics is needed to improve therapy. Cancer 2006. © 2005 American Cancer Society.